Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Practical applications of integrated microfluidics for peptide quantification.

Chambers EE, Lame ME, Rainville PD, Murphy J, Johnson J, Fountain KJ, Plumb RS, Claise P, Smith NW.

Bioanalysis. 2015;7(7):857-67. doi: 10.4155/bio.15.15.

PMID:
25932520
2.

High sensitivity LC-MS/MS method for direct quantification of human parathyroid 1-34 (teriparatide) in human plasma.

Chambers EE, Lame ME, Bardsley J, Hannam S, Legido-Quigley C, Smith N, Fountain KJ, Collins E, Thomas E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Nov 1;938:96-104. doi: 10.1016/j.jchromb.2013.08.027. Epub 2013 Sep 3.

PMID:
24076523
3.

Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry.

Lame ME, Chambers EE, Blatnik M.

Anal Biochem. 2011 Dec 15;419(2):133-9. doi: 10.1016/j.ab.2011.08.010. Epub 2011 Aug 12.

PMID:
21888888
4.

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.

Elliott RL, Cameron KO, Chin JE, Bartlett JA, Beretta EE, Chen Y, Jardine Pda S, Dubins JS, Gillaspy ML, Hargrove DM, Kalgutkar AS, LaFlamme JA, Lame ME, Martin KA, Maurer TS, Nardone NA, Oliver RM, Scott DO, Sun D, Swick AG, Trebino CE, Zhang Y.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6797-801. doi: 10.1016/j.bmcl.2010.08.115. Epub 2010 Sep 28.

PMID:
20851601
5.

Modification of amyloid-beta(1-40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-beta(1-42).

Conboy JJ, Wood KG, Lame ME, Durham RA, Geoghegan KF.

Anal Biochem. 2008 Nov 15;382(2):147-9. doi: 10.1016/j.ab.2008.07.033. Epub 2008 Aug 5.

PMID:
18706385
6.

Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.

Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV Jr, Soliman VF, Schildknegt K.

Drug Metab Dispos. 2007 Jun;35(6):848-58. Epub 2007 Mar 7.

PMID:
17344339
8.

Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.

Girard D, Finegan SM, Dunne MW, Lame ME.

J Antimicrob Chemother. 2005 Aug;56(2):365-71. Epub 2005 Jul 7.

PMID:
16002421
9.

Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4.

Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE.

Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18.

PMID:
15978881
10.

Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4.

Kalgutkar AS, Vaz AD, Lame ME, Henne KR, Soglia J, Zhao SX, Abramov YA, Lombardo F, Collin C, Hendsch ZS, Hop CE.

Drug Metab Dispos. 2005 Feb;33(2):243-53. Epub 2004 Nov 2. Erratum in: Drug Metab Dispos. 2005 May;33(5):696.

PMID:
15523046
11.
12.

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3389-95.

PMID:
15177439

Supplemental Content

Support Center